Chen D, et al. (2019) Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer. Cancer Discov 9 30862724

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

Y42-p - IDH1 (human) ▲

Modsite: VELDLHsyDLGIENR SwissProt Entrez-Gene Orthologous residues IDH1 (human): Y42‑p, IDH1 (mouse): Y42‑p, IDH1 (rat): Y42‑p Characterization Methods used to characterize site in vivo:  immunoassay, mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  leukemia, acute myelogenous leukemia, acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b), acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b), chronic myelogenous leukemia, lung cancer, non-small cell lung cancer Relevant cell lines - cell types - tissues:  HEL (erythroid), K562 (erythroid), MOLM-14 (myeloid), MV4-11 (macrophage), NCI-H1299 (pulmonary), TF-1 (erythroid) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme KINASE FGFR1 (human) Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes dovitinib decrease imatinib decrease AG490 decrease quizartinib decrease ruxolitinib decrease PTP1B (human) decrease Downstream Regulation Effect of modification (function):  molecular association, regulation Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays IDH1 (human) Induces

Y391-p - IDH1 (human) ▲

Modsite: PNVQRsDyLNTFEFM SwissProt Entrez-Gene Orthologous residues IDH1 (human): Y391‑p, IDH1 (mouse): Y391‑p, IDH1 (rat): Y391‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  leukemia, acute myelogenous leukemia, acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b), acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b), chronic myelogenous leukemia, lung cancer, non-small cell lung cancer Relevant cell lines - cell types - tissues:  HEL (erythroid), K562 (erythroid), MOLM-14 (myeloid), MV4-11 (macrophage), NCI-H1299 (pulmonary), TF-1 (erythroid) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme KINASE FLT3 (human) Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes dovitinib decrease imatinib decrease AG490 decrease quizartinib decrease ruxolitinib no change compared to control PTP1B (human) decrease Downstream Regulation Effect of modification (function):  molecular association, regulation Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays Induces Comments:  cofactor NADP+ binding to IDH1